Clinical application of nanoparticles, and their possible health risk;A nanorészecskék klinikai alkalmazási lehetoségei és lehetséges veszélyei

Orvosi Hetilap

Volumn 149, Issue 38, 2008, Pages 1785-1790

  Pándics, Tamás ^a,b  

^a Molekuláris Genetikai és Diagnosztíkai Osztály   (Hungary)

^b NONE   (Hungary)

Author keywords

Health risk assessment; Nanomedicine; Nanoparticles; Risk factors

Indexed keywords

LIPOSOME; NANOMATERIAL; NANOPARTICLE; REACTIVE OXYGEN METABOLITE;

CARDIOVASCULAR RISK; CLINICAL PRACTICE; HUMAN; MATERIAL COATING; MEDICAL CARE; NANOBIOTECHNOLOGY; NANOMEDICINE; NANOPHARMACEUTICS; QUALITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE AGGREGATION;

EID: 53849109221     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2008.28458     Document Type: Review

References (41)

1. Paschen, H.: Überblick über wichtige Anwendungsfelder. In: Nanotechnologie. Szerk.: Paschen, H., Coenen, C., Fleischer, T. és mtsai. Springer-Verlag; Berlin, Heidelberg, New York, 2004, 282-294.
2. SCENIHR: Opinion on methodology in accordance with the technical guidance documents for new and existing substances for assessing the risks of nanomaterials, 19th plenary on 21-22 June 2007, European Commission, Health and Consumer Protection Directorate-General, Brussels, 2007, 14-44.
3. Sachse, A.: Induzierte Osteointegration rhBMP-2-beschichteter Hydroxyapatit-Titan-Zylinder bei alten Schafen. Deutscher Kongress für Orthopädie und Unfallchirurgie, Meeting Abstract, 2006.
4. Nair, L. S., Laurencin, C. T.: Nanofibers and nanoparticles for orthopaedic surgery applications. J. Bone Joint Surg. Am., 2008, 90, 128-131.
5. Laschke, M. W., Witt, K., Pohlemann, T. és mtsai: Injectable nanocrystalline hydroxyapatite paste for bone substitution: in vivo analysis of biocompatibility and vascularization. J. Biomed. Mater. Res. B. Appl. Biomater., 2007, 82, 494-505.
6. Vlachou, E., Chipp, E., Shale, E. és mtsai: The safety of nanocrystalline silver dressings on burns: a study of systemic silver absorption. Burns, 2007, 33, 979-985.
7. Bhattacharyya, M., Bradley, H.: A case report of the use of nanocrystalline silver dressing in the management of acute surgical site wound infected with MRSA to prevent cutaneous necrosis following revision surgery. Int. J. Low Extrem. Wounds, 2008, 7, 45-48.
8. Sibbald, R. G., Contreras-Ruiz, J., Coutts, P. és mtsai: Bacteriology, inflammation, and healing: a study of nanocrystalline silver dressings in chronic venous leg ulcers. Adv. Skin Wound Care, 2007, 20, 549-558.
9. Meirelles, L., Melin, L., Peltola, T. és mtsai: Effect of hydroxyapatite and titania nanostructures on early in vivo bone response. Clin. Implant. Dent. Relat. Res., 2008 Apr 1.
10. Gessler T., Seeger, W., Schmehl, T.: Inhaled prostanoids in the therapy of pulmonary hypertension. J. Aerosol. Med. Pulm. Drug Deliv., 2008, 21, 1-12.
11. Bhol, K. C., Schechter, P. J.: Effects of nanocrystalline silver (NPI 32101) in a rat model of ulcerative colitis. Dig. Dis. Sci., 2007, 10, 32-42.
12. Nafee, N., Taetz, S., Schneider, M. és mtsai: Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine, 2007, 3, 173-183.
13. Serda, R. E., Adolphi, N. L., Bisoffi, M. és mtsai: Targeting and cellular trafficking of magnetic nanoparticles for prostate cancer imaging. Mol. Imaging, 2007, 4, 277-288.
14. Lanza, G., Winter, P., Cyrus, T. és mtsai: Nanomedicine opportunities in cardiology. Ann. N. Y. Acad. Sci., 2006, 1080, 451-465.
15. Bennat, C., Müller-Goymann, C. C.: Skin penetration and stabilisation of formulations containing microfine titanium dioxide as physical UV filter. Int. J. Cosmet. Sci., 2000, 22, 271-283.
16. Tinkle, S. S.: Skin as a route of exposure and sensitization in chrinic beryllium disease. Environ. Health Perspect., 2003, 111, 1202-1208.
17. Tsuji, J.: Research strategies for safety evaluation of nanomaterials, Part IV: Risk Assessment of Nanoparticles. Toxic. Sci., 2006, 89, 42-50.
18. Maynard, D.: Nanotechnology: assessing the risks. Nanotoday, 2006, 1, 22-33.
19. International Commission on Radiological Protection. Human respiratory tract model for radiological protection. Ann. ICRP24, 1994, 1-300.
20. Ferin, J., Oberdörster, G.: Translocation of particles from pulmonary alveoli into the interstitium. J. Aerosol Med., 1992, 5, 179-187.
21. Oberdorster, G., Sharp, Z., Atudorei, V. és mtsai: Extrapulmonary translocation of ultrafine carbon particles following whole-body inhalation exposure of rats. J. Toxicol. Environ. Health A, 2002, 65, 1531-1543.
22. Oberdörster, G.: Toxicology of ultrafine particles: in vivo studies. Philos. Trans. R. Soc. Lond. A, 2000, 358, 2719-2740.
23. Hu, J., Liu, Z. S., Tang, S. L. és mtsai: Effect of hydroxyapatite nanoparticles on the growth and p53/c-Myc protein expression of implanted hepatic VX2 tumor in rabbits by intravenous injection. World J. Gastroenterol., 2007, 13, 2798-2802.
24. Yamago, S., Tokuyama, H., Nakamura, E. és mtsai: In vivo biological behavior of a water-miscible fullerene: 14C labeling, adsorption, distribution, excretion and acute toxicity. Chem. Biol., 1995, 2, 385-389.
25. Kreuter, J., Shamenkov, D., Petrov, V. és mtsai: Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target, 2002, 10, 317-325.
26. Long, T., Saleh, N., Tilton, R. és mtsai: Titanium dioxide (P25) produces reactive oxygen species in immortalized brain microglia (BV2): Implications for nanoparticle neurotoxicity. Environ. Sci. Tech., 2006, 40, 4346-4352.
27. Sharma, H., Sharma, A.: Nanoparticles aggravate heat stress induced cognitive deficits, blood-brain barrier disruption, edema formation and brain pathology. Prog. Brain Res., 2007, 162, 245-273.
28. Bauer, I. W., Li, S. P., Han, Y. C. és mtsai: Internalization of hydroxyapatite nanoparticles in liver cancer cells. J. Mater. Sci. Mater. Med., 2008, 19, 1091-1095.
29. Hussain, S. M., Hess, K. L., Gearhart, J. M. és mtsai: In vitro toxicity of nanoparticles in BRL 3A rat liver cells. Toxicol. In Vitro, 2005, 19, 975-983.
30. Sayes, C. M., Reed, K. L., Warheit, D. B.: Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles. Toxicol. Sci., 2007, 97, 163-180.
31. Feikert, T., Mercer, P., Corson, N. és mtsai: Inhaled solid ultrafine particles (UFP) are efficiently translocated via neuronal nasoolfactory pathways. Toxicologist, 2004, 78, 435-436.
32. Nemmar, A., Hoylaerts, M. F., Hoet, P. H. és mtsai: Size effect of intratracheally instilled particles on pulmonary inflammation and vascular thrombosis. Toxicol. Appl. Pharmacol., 2003, 186, 38-45.
33. Muldoon, L. L., Manninger, S., Pinkston, K. E. és mtsai: Imaging, distribution and toxicity of iron oxide magnetic resonance agents in rat brain and intracerebral tumor. Neurosurgery, 2005, 57, 785-795.
34. Ashwini, S., Önyüksel, R.: PEGylated phospholipid nanomicelles interact with β-amyloid and mitigate its β-sheet formation, aggregation and neurotoxicity in vitro. Peptides, 2006, 27, 2858-2866.
35. Singh, P., Prasuhn, D., Yeh, R. M. és mtsai: Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo. J. Control. Release, 2007, 120, 41-50.
36. Fabian, E., Landsiedel, R., Ma-Hock, L. és mtsai: Tissue distribution and toxicity of intravenously administered titanium dioxide nanoparticles in rats. Arch. Toxicol., 2008, 82, 151-157.
37. Sung, J. H., Ji, J. H., Yoon, J. U. és mtsai: Lung function changes in Sprague-Dawley rats after prolonged inhalation exposure to silver nanoparticles. Inhal. Toxicol., 2008, 20, 567-574.
38. Wang, J. J., Sanderson, B. J., Wang, H.: Cyto- and genotoxicity of ultrafine TiO2 particles in cultured human lymphoblastoid cells. Mutat. Res., 2007, 628, 99-106.
39. Warheit, D. B., Hoke, R. A., Finlay, C. és mtsai: Development of a base set of toxicity tests using ultrafine TiO2 particles as a component of nanoparticle risk management. Toxicol. Lett., 2007, 171, 99-110.
40. Nohynek, G. J., Lademann, J., Ribaud, C. és mtsai: Grey goo on the skin? Nanotechnology, cosmetic and sunscreen safety. Crit. Rev. Toxicol., 2007, 37, 251-277.
41. Ren, L., Huang, X. L., Zhang, B.: Cisplatin-loaded Au-Au(2)S nanoparticles for potential cancer therapy: Cytotoxicity, in vitro carcinogenicity, and cellular uptake. J. Biomed. Mater. Res. A, 2008, 85, 787-796.